Rethinking Pharma Commercial Targeting with AI - with Philip Poulidis of ODAIA (29 min)
- Release date: 2026-03-04
- Listen on Spotify: Open episode
- Episode description:
Commercial life‑sciences teams are facing a widening gap between strong brand strategy and fragmented real‑world execution, driven by misaligned workflows, static targeting, and an inability to act at the speed patients move through their therapeutic journeys. In this episode, Philip Poulidis, CEO and Co-founder of ODAIA, unpacks how AI can close that gap by connecting brand intent to real‑time execution, enabling teams to prioritize the right HCPs, orchestrate engagement, and measure impact through outcomes rather than activity metrics. He highlights the practical shifts required to get there — from cross‑functional adoption and workflow‑embedded insights to attribution modeling, efficiency gains, and focused pilots that prove value quickly. This episode is sponsored by ODAIA. Learn how brands work with Emerj and other Emerj Media options at emerj.com/partner. Want to share your AI adoption story with executive peers? Click emerj.com/expert for more information and to be a potential future guest on the 'AI in Business' podcast!
Summary
- 🔄 Strategy-Execution Drift: Pharma brand plans falter post-handoff due to team misalignment and dynamic patient/HCP shifts; AI reconnects them via real-time prediction.
- 🎯 Real-Time Prioritization: AI processes trillions of data points to rank HCPs and orchestrate omnichannel efforts, targeting moments that influence prescriptions.
- 🔗 Workflow Embedding: AI succeeds when integrated into CRM and daily tools, not silos, accelerating reps while respecting their expertise.
- 📊 Outcome KPIs: Ditch activity metrics for attribution models linking engagements to therapy starts, slashing waste like $5B in irrelevant spends.
- 🚀 Adoption Roadmap: Start with problem-focused pilots, cross-functional teams, and domain-expert partners to overcome data myths and scale quickly.
Insights
Why do even the strongest pharma brand strategies drift apart from real-world execution?
Time: 3:58 – 5:33
Category: AI for Personalized MedicineAnswer: Pharma companies invest heavily in detailed brand plans aligned to patient journeys, but after handoff to sales, marketing, and field teams, interpretations diverge, causing misalignment as patient paths, HCP behaviors, and market conditions shift rapidly. AI bridges this gap by enabling real-time tracking and prediction to keep execution synced with strategy. (Start at 3:58)
How can AI turn massive patient and HCP data into actionable targeting for better outcomes?
Time: 5:34 – 6:23
Category: AI for Personalized MedicineAnswer: AI analyzes trillions of data points from claims, labs, and behaviors to identify eligible patients responding better to specific therapies and prioritize HCPs accordingly, allowing pharma to focus efforts where they influence prescriptions and adherence most. This shifts execution from months to days. (Start at 5:34)
What’s killing most enterprise AI initiatives, and how can pharma avoid it?
Time: 7:58 – 10:38
Category: AI in Workforce DisruptionAnswer: Over 90% fail due to poor workflow integration, per MIT study; success comes from embedding AI into daily tools for real-time prioritization of field and digital engagements, reducing waste like $5B in irrelevant US provider spend. AI acts as an accelerant, enhancing reps’ judgment without replacement. (Start at 7:58)
Are pharma’s traditional activity metrics like open rates still relevant in the AI era?
Time: 13:05 – 14:19
Category: AI-Driven Innovation EconomyAnswer: No—shift to outcome attribution linking engagement sequences to prescriptions and patient starts on therapy, moving beyond vanity metrics to measure if actions deliver right treatments at critical moments. This reveals inefficiencies like 80 disconnected touchpoints overwhelming one HCP monthly. (Start at 13:05)
What’s the smartest first step for pharma execs championing commercial AI?
Time: 18:31 – 21:02
Category: AI-Driven Innovation EconomyAnswer: Identify a specific revenue or patient-impact problem, assemble cross-functional teams (sales, marketing, IT, legal), run tight pilots with clear KPIs, and embed insights into existing CRM/workflows—not standalone tools—to prove value fast and build momentum. Data readiness excuses are myths; partners handle it. (Start at 18:31)
Does domain expertise matter more than general tools for AI in pharma data challenges?
Time: 24:51 – 26:28
Category: AI for Personalized MedicineAnswer: Yes—vertical providers like ODAIA use feature stores to leapfrog data cleansing/labeling into life sciences-specific feature engineering, creating thousands of tailored features for commercial models far faster than horizontal solutions or internal teams. (Start at 24:51)